Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

Abstract

Picoplatin demonstrated clinical efficacy in platinum-refractory SCLC. The major toxicity was hematologic. These results warrant further evaluation in this patient population.